DSM, Crucell Sign Licensing Deal with Taiwanese DCB
Published March 26, 2007
Related Searches: Industry News •
DSM Biologics and Crucell N.V. have signed a non-exclusive PER.C6 research licensing deal with Taipei, Taiwan-headquartered Development Center for Biotechnology (DCB). DCB will use the human cell line for its in-house production of undisclosed recombinant proteins. This PER.C6 license is Crucell's second license in Taiwan for recombinant protein production. The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products including vaccines.
blog comments powered by Disqus